• 1
    Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet, 2003;361:15451551.
  • 2
    Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti Infect Ther, 2010;8:12931305.
  • 3
    Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev, 2004;20(Suppl 1):S68S77.
  • 4
    Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care, 1999;22:382387.
  • 5
    Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care, 1999;22:13541360.
  • 6
    Bloomgarden ZT. The diabetic foot. Diabetes Care, 2008;31:372376.
  • 7
    Reiber GE. The epidemiology of diabetic foot problems. Diabet Med, 1996;13(Suppl 1):S6S11.
  • 8
    Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA, 2005;293:217228.
  • 9
    Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2004a;39:885910.
  • 10
    Lipsky BA, Berendt AR, Cornia PB et al. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis, 2012;54:e132e173.
  • 11
    Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care, 2006;29:12881293.
  • 12
    Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care, 1990;13:513521.
  • 13
    Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes, 1991;40:13051313.
  • 14
    Pinzur MS, Pinto MA, Schon LC, Smith DG. Controversies in amputation surgery. Instr Course Lect, 2003;52:445451.
  • 15
    Scher KS, Steele FJ. The septic foot in patients with diabetes. Surgery, 1988;104:661666.
  • 16
    Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis, 2011;52:12321240.
  • 17
    Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward a rational definition. Diabet Med, 2003;20:329331.
  • 18
    Sadat U, Chaudhuri A, Hayes PD, Gaunt ME, Boyle JR, Varty K. Five day antibiotic prophylaxis for major lower limb amputation reduces wound infection rates and the length of in-hospital stay. Eur J Vasc Endovasc Surg, 2008;35:7578.
  • 19
    Hall JC, Christiansen KJ, Goodman M et al. Duration of antimicrobial prophylaxis in vascular surgery. Am J Surg, 1998;175:8790.
  • 20
    Earnshaw JJ, Slack RC, Hopkinson BR, Makin GS. Risk factors in vascular surgical sepsis. Ann R Coll Surg Engl, 1988;70:139143.
  • 21
    Grayson ML, Gibbons GW, Habershaw GM et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis, 1994;18:683693.
  • 22
    Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents, 2005;26:357365.
  • 23
    Harkless L, Boghossian J, Pollak R, Caputo W, Dana A, Gray S, Wu D. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt), 2005;6:2740.
  • 24
    Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis, 2004b;38:1724.
  • 25
    Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother, 2005;55:240245.
  • 26
    Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet, 2005;366:16951703.
  • 27
    Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother, 2007;60:370376.
  • 28
    Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis, 2008;47:15371545.
  • 29
    Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis, 2008;46:647655.
  • 30
    Saltoglu N, Dalkiran A, Tetiker T, Bayram H, Tasova Y, Dalay C, Sert M. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect, 2010;16:12521257.